Literature DB >> 24121499

Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Mikael Larsson1, Evelina Vorrsjö1, Philippa Talmud2, Aivar Lookene3, Gunilla Olivecrona4.   

Abstract

Apolipoproteins (apo) C-I and C-III are known to inhibit lipoprotein lipase (LPL) activity, but the molecular mechanisms for this remain obscure. We present evidence that either apoC-I or apoC-III, when bound to triglyceride-rich lipoproteins, prevent binding of LPL to the lipid/water interface. This results in decreased lipolytic activity of the enzyme. Site-directed mutagenesis revealed that hydrophobic amino acid residues centrally located in the apoC-III molecule are critical for attachment to lipid emulsion particles and consequently inhibition of LPL activity. Triglyceride-rich lipoproteins stabilize LPL and protect the enzyme from inactivating factors such as angiopoietin-like protein 4 (angptl4). The addition of either apoC-I or apoC-III to triglyceride-rich particles severely diminished their protective effect on LPL and rendered the enzyme more susceptible to inactivation by angptl4. These observations were seen using chylomicrons as well as the synthetic lipid emulsion Intralipid. In the presence of the LPL activator protein apoC-II, more of apoC-I or apoC-III was needed for displacement of LPL from the lipid/water interface. In conclusion, we show that apoC-I and apoC-III inhibit lipolysis by displacing LPL from lipid emulsion particles. We also propose a role for these apolipoproteins in the irreversible inactivation of LPL by factors such as angptl4.

Entities:  

Keywords:  Apolipoprotein C-I; Apolipoprotein C-III; Apolipoproteins; Dyslipidemia; Lipolysis; Lipoprotein; Lipoprotein Lipase; Lipoprotein Metabolism; Triglyceride

Mesh:

Substances:

Year:  2013        PMID: 24121499      PMCID: PMC3837139          DOI: 10.1074/jbc.M113.495366

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

1.  Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen.

Authors:  Wen Qin; Meenakshi Sundaram; Yuwei Wang; Hu Zhou; Shumei Zhong; Chia-Ching Chang; Sanjay Manhas; Erik F Yao; Robin J Parks; Pamela J McFie; Scot J Stone; Zhenghui G Jiang; Congrong Wang; Daniel Figeys; Weiping Jia; Zemin Yao
Journal:  J Biol Chem       Date:  2011-06-15       Impact factor: 5.157

2.  Triacylglycerol-rich lipoproteins protect lipoprotein lipase from inactivation by ANGPTL3 and ANGPTL4.

Authors:  Stefan K Nilsson; Fredrick Anderson; Madelene Ericsson; Mikael Larsson; Elena Makoveichuk; Aivar Lookene; Joerg Heeren; Gunilla Olivecrona
Journal:  Biochim Biophys Acta       Date:  2012-06-21

3.  Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart.

Authors:  Xinxin Yu; Shawn C Burgess; Hongfei Ge; Kenny K Wong; R Haris Nassem; Daniel J Garry; A Dean Sherry; Craig R Malloy; Joel P Berger; Cai Li
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-19       Impact factor: 11.205

4.  Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII.

Authors:  Yinyuan Ding; Yuhui Wang; Hong Zhu; Jianglin Fan; Liqing Yu; George Liu; Enqi Liu
Journal:  Transgenic Res       Date:  2010-12-01       Impact factor: 2.788

5.  Activator proteins for lipoprotein lipase from bovine plasma: preparation by adsorption to Intralipid.

Authors:  H N Astrup; G Bengtsson
Journal:  Comp Biochem Physiol B       Date:  1982

6.  Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages.

Authors:  Laeticia Lichtenstein; Frits Mattijssen; Nicole J de Wit; Anastasia Georgiadi; Guido J Hooiveld; Roelof van der Meer; Yin He; Ling Qi; Anja Köster; Jouke T Tamsma; Nguan Soon Tan; Michael Müller; Sander Kersten
Journal:  Cell Metab       Date:  2010-12-01       Impact factor: 27.287

7.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

Authors:  Y Ito; N Azrolan; A O'Connell; A Walsh; J L Breslow
Journal:  Science       Date:  1990-08-17       Impact factor: 47.728

8.  Interaction of plasma apolipoproteins with lipid monolayers.

Authors:  R L Jackson; F Pattus; R A Demel
Journal:  Biochim Biophys Acta       Date:  1979-10-05

9.  Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice.

Authors:  W S Simonet; N Bucay; R E Pitas; S J Lauer; J M Taylor
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

10.  Forms of lipoprotein lipase in rat tissues: in adipose tissue the proportion of inactive lipase increases on fasting.

Authors:  M Bergö; G Olivecrona; T Olivecrona
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

View more
  60 in total

1.  Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Authors:  Nathan L Meyers; Mikael Larsson; Evelina Vorrsjö; Gunilla Olivecrona; Donald M Small
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

Review 2.  Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Authors:  Werner J Geldenhuys; Li Lin; Altaf S Darvesh; Prabodh Sadana
Journal:  Drug Discov Today       Date:  2016-10-19       Impact factor: 7.851

3.  Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.

Authors:  Arman Qamar; Sumeet A Khetarpal; Amit V Khera; Atif Qasim; Daniel J Rader; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-11       Impact factor: 8.311

4.  ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Authors:  Philip L S M Gordts; Ryan Nock; Ni-Huiping Son; Bastian Ramms; Irene Lew; Jon C Gonzales; Bryan E Thacker; Debapriya Basu; Richard G Lee; Adam E Mullick; Mark J Graham; Ira J Goldberg; Rosanne M Crooke; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

5.  Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes.

Authors:  Robert A Hegele
Journal:  J Lipid Res       Date:  2016-07-13       Impact factor: 5.922

6.  Unusual Dyslipidemia in Patients with Chronic Kidney Diseases.

Authors:  Rashmi Rekha Phukan; Rohini K Goswami
Journal:  J Clin Diagn Res       Date:  2017-01-01

7.  High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts.

Authors:  Majken K Jensen; Sarah A Aroner; Kenneth J Mukamal; Jeremy D Furtado; Wendy S Post; Michael Y Tsai; Anne Tjønneland; Joseph F Polak; Eric B Rimm; Kim Overvad; Robyn L McClelland; Frank M Sacks
Journal:  Circulation       Date:  2017-11-21       Impact factor: 29.690

8.  A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Authors:  Sumeet A Khetarpal; Xuemei Zeng; John S Millar; Cecilia Vitali; Amritha Varshini Hanasoge Somasundara; Paolo Zanoni; James A Landro; Nicole Barucci; William J Zavadoski; Zhiyuan Sun; Hans de Haard; Ildikó V Toth; Gina M Peloso; Pradeep Natarajan; Marina Cuchel; Sissel Lund-Katz; Michael C Phillips; Alan R Tall; Sekar Kathiresan; Paul DaSilva-Jardine; Nathan A Yates; Daniel J Rader
Journal:  Nat Med       Date:  2017-08-21       Impact factor: 53.440

9.  Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations.

Authors:  Josephine Chiu; Kristin N Valente; Nicholas E Levy; Lie Min; Abraham M Lenhoff; Kelvin H Lee
Journal:  Biotechnol Bioeng       Date:  2016-12-27       Impact factor: 4.530

10.  18O proteomics reveal increased human apolipoprotein CIII in Hispanic HIV-1+ women with HAART that use cocaine.

Authors:  Frances Zenón; Inmaculada Jorge; Ailed Cruz; Erick Suárez; Annabell C Segarra; Jesús Vázquez; Loyda M Meléndez; Horacio Serrano
Journal:  Proteomics Clin Appl       Date:  2015-11-19       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.